HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1964 BMS-986365 BMS-986365 (CC-94676) is a potent and selective, heterobifunctional ligand-directed degrader (LDD) and antagonist of androgen receptor (AR), that effectively targets both wildtype and mutant forms of the androgen receptor (AR) in the cytoplasm and nucleus. It rapidly degrades AR, suppresses AR signaling, and shows promising clinical activity in inhibiting tumor growth in patients with metastatic castration-resistant prostate cancer (mCRPC). Aug 18 2024
E1899 INCB059872 dihydrochloride INCB059872 dihydrochloride is a potent, selective, and irreversible inhibitor of Lysine-Specific Demethylase 1(LSD1). It exhibits potential antineoplastic activity and can be used in acute myeloid leukemia (AML) research. Aug 18 2024
E4877 Lefamulin Lefamulin (BC-3781), is a pleuromutilin antibiotic, inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome. It is effective against a range of gram-positive pathogens involved in community-acquired bacterial pneumonia (CABP), including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, Chlamydophila pneumoniae, Staphylococcus aureus (including methicillin-resistant and vancomycin-intermediate strains), and vancomycin-resistant Enterococcus faecium. Aug 18 2024
S8143 Mavoglurant Mavoglurant (AFQ056) is a structurally selective, non-competitive antagonist of mGlu5 receptor with an IC50 of 30 nM. It exhibits efficacy in treatment of L-dopa induced dyskinesia in Parkinson's disease and Fragile X syndrome. Aug 18 2024
E1847 GBD-9 GBD-9 is a double-mechanism efficient degrader of BTK and GSPT1 by recruiting the E3 ligase cereblon (CRBN). GBD-9 acts both as a PROTAC molecule to induce the degradation of BTK and as a molecular glue to degrade GSPT1.It exhibits anti-proliferative effects, inhibiting cancer cell survival. Aug 15 2024
E1683 DN02 DN02 is a selective probe of BRD8 bromodomain family. It exhibits potency against BRD8(1) with a Kd of 32 nM, and interestingly, demonstrated this activity to be selective over BRD8's second bromodomain (BRD8(2) with a Kd of >1000 nM) Aug 15 2024
E4843 Vardenafil dihydrochloride Vardenafil dihydrochloride is a potent, and selective inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. It also exhibits inhibition of PDE1 and PDE6 with IC50 of 180 nM and 11 nM respectively. It can be used for the research of erectile dysfunction, hepatitis, diabetes. Aug 15 2024
E1612 Suzetrigine VX-548 (Suzetrigine), is an oral, highly selective inhibitor of voltage-gated sodium channel 1.8 (NaV1.8) with an IC50 of 0.7 nM. It can be used in research of transmitting nociceptive signals and treatment of acute pain after abdominoplasty or bunionectomy. Aug 15 2024
E1951 X5050 X5050 is a benzoimidazole-5-carboxamide derivative and a potent inhibitor of repressor element-1 silencing transcription factor (REST) with an EC50 of 2.1 μM. It can be used in research of Huntington's disease and other neurodegenerative disorders characterized by altered BDNF levels. Aug 15 2024
E4858 Rimonabant hydrochloride Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective antagonist of the central cannabinoid receptor (CB1) , with a Ki of 1.8 nM. It is an anorectic anti-obesity drug with potential to treat obesity and cardiovascular risk factors. Aug 15 2024
E4842 Vilanterol Vilanterol (GW642444) is a potent and selective agonist of β2-adrenoceptor (β2-AR) with pEC50 of β2-AR, β1-AR, and β3-AR is 10.37, 6.98 and 7.36 respectively in cAMP detection assays. Aug 15 2024
E4846 Treprostinil Treprostinil is a potent agonist of DP1 and EP2  with EC50 of 0.6 nM and 6.2 nM for DP1 and EP2 receptors, respectively. It is a vasodilator used to treat pulmonary arterial hypertension and improves mitochondrial impairment in vitro. Aug 15 2024
E1997 GLPG3970 GLPG3970 (compound 32) is a dual inhibitor of SIK2 and SIK3, with IC50 of 282.8 nM, 7.8 nM and 3.8 nM for SIK1, SIK2 and SIK3, respectively. It has the potential to treat autoimmune and inflammatory diseases. Aug 15 2024
E4870 Naratriptan Naratriptan is an agonist of 5-hydroxytryptamine1B/D (5-HT1B/D) receptors, which reduces the frequency of cluster headache. Aug 15 2024
E4866 Paroxetine Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety disorders. It inhibits pyroptosis and reduces osteoclast formation by blocking the NF-κB signalling pathway. Aug 15 2024
E1560 Raptinal Raptinal is a pro-apoptotic compound that induces apoptosis by promoting the release of cytochrome c from the mitochondria, thereby activating the intrinsic apoptotic pathway. It also inhibits the activity of caspase-activated Pannexin 1 (PANX1), a ubiquitously expressed transmembrane channel involved in regulating various cell death-associated processes. Aug 15 2024
E4868 Olsalazine Olsalazine is a salicylic acid-derived anti-inflammatory agent used to treat ulcerative colitis. Aug 15 2024
E4852 Tafamidis meglumine Tafamidis meglumine (Vyndaqel, Fx-1006A) stabilizes the tetrameric structure of transthyretin (TTR) by binding to thyroxine-binding sites. Tafamidis meglumine treats transthyretin familial amyloid polyneuropathies (TTR-FAP), a condition characterized by neurological damage from TTR amyloidosis, by preventing the misfolding and aggregation of transthyretin (TTR) into amyloid fibrils. Aug 12 2024
E1902 Nedometinib Nedometinib (NFX-179) is a highly specific and potent inhibitor of MEK1 with an IC50 of 135 nM. It also results in suppression of p-ERK levels and can be used in research and treatment of cutaneous neurofibromas (cNFs) associated with neurofibromatosis type 1 (NF1). Aug 12 2024
E1355 JNJ-64264681 JNJ-64264681 is an orally active, irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK) with potent whole blood activity and exceptional kinome selectivity. It exhibits potential efficacy in treatment for B-cell malignancies and autoimmune disorders. Aug 12 2024